Navigation Links
Two Antidepressants Given to Dementia Patients Ineffective: Study
Date:7/19/2011

By Alan Mozes
HealthDay Reporter

TUESDAY, July 19 (HealthDay News) -- The antidepressants most often prescribed to treat depression in dementia patients provide no appreciable relief, and may raise the risk for serious side effects, new British research suggests.

"The two classes of antidepressants most likely to be prescribed for depression in Alzheimer's disease are no more effective than placebo," the study authors said.

The drugs in question are Zoloft (sertraline), and Remeron (mirtazapine).

"In our study, there were more adverse reactions in individuals treated with antidepressants than there were with placebo," the research team added. "Clinicians and investigators need to reframe the way they think about the treatment of people with Alzheimer's disease who are depressed, and reconsider routine prescription of antidepressants."

Led by Sube Banerjee of the Institute of Psychiatry at Kings College London in England, the authors reported their findings online July 19 in The Lancet.

Banerjee and his colleagues focused on 325 patients being treated at any of nine health centers across England for probable or possible Alzheimer's disease. The patients were also subject to bouts of depression lasting at least a month, and all registered above a minimum threshold during dementia-related depression exams.

None had been prescribed antidepressants prior to the study launch, nor were any in a critical stage of depression involving suicidal thoughts.

The patients were divided into three 13-week treatment groups. One group received 150 milligrams (mg) a day of sertraline; a second group received 45 mg a day of mirtazapine; and a third took sugar pills (placebos).

After three months, the authors found no difference in the incidence of depression among the three groups. The lack of an apparent benefit attributable to either sertraline or mirtazapine continued almost 10 months after the study's start, according to a journal news release.

Also, while about a quarter of those given placebos experienced adverse reactions as a result of treatment, that figure rose to between 41 percent and 43 percent in the groups given an antidepressant. Such side effects were also more likely to be serious among the antidepressant recipients than among the placebo group.

Dr. Henry Brodaty, an aging and dementia specialist at the University of New South Wales in Sydney, Australia, and author of an accompanying journal editorial, said the trial "has underscored the need for clinicians to think about creative alternatives to drug treatment for management of depression in people with dementia." It is important to use evidence-based techniques and to work in partnership with family caregivers, he wrote in the news release.

More information

For more on dementia and depression, visit the Alzheimer's Society.

--Alan Mozes

SOURCE: July 19, 2011, The Lancet, news release


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Research reveals that 10 percent of middle-aged Europeans are on antidepressants
2. Common Painkillers May Blunt Antidepressants
3. Antidepressants may not improve all symptoms of depression, UT Southwestern researchers find
4. U. Iowa study suggests antidepressants aid physical recovery in stroke
5. Study Hints at Link Between Antidepressants and Heart Trouble
6. Antidepressants linked to thicker arteries
7. Decrease in suicide not linked to newer antidepressants
8. Autism: Lack of evidence for antidepressants
9. Certain Popular Antidepressants Linked to Cataracts in Seniors
10. Antidepressants in pregnancy increase risk of miscarriage
11. Antidepressants May Improve Heart Health
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Two Antidepressants Given to Dementia Patients Ineffective: Study  
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... the alternative health care industry, announces Chris Brandl as its New Guest Director. ... vision and purpose to corporations throughout his career. He began his professional career ...
(Date:2/27/2017)... ... February 27, 2017 , ... The threat of nuclear ... work for a company involved in the underground testing of nuclear weapons. Years later, ... Answers: Expendable Workers of the Cold War Nuclear Testing,” Clayton exposes the critical decisions ...
(Date:2/27/2017)... ... 2017 , ... Miro is the ultimate smart media center that offers a ... TV shows and much more apps for user exploration. Its innovative acoustic design with ... 1280 x 720 provides crisp images with remarkable clarity and color. The WiFi connection ...
(Date:2/27/2017)... Francisco, CA (PRWEB) , ... February 27, 2017 ... ... center for hair transplantation therapy, is proud to announce a new informational post ... hair therapy procedures. Follicular Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation ...
(Date:2/26/2017)... ... 26, 2017 , ... Today, A' Design Awards & Competition ... Social Design Awards. , The 7th A' Social Design Award is open ... worldwide with realized projects and conceptual works. , The first phase of the ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 27, 2017  International Biophysics Corporation, a global medical device ... announced a 34% revenue growth in 2016 when compared to ... sales.  This growth was fueled by its AffloVest® sales in ... the expansion of its global sales of surgical product lines. ... "As we enter our 25 th year in delivering ...
(Date:2/27/2017)... ROCKVILLE, Md. , Feb. 27, 2017 /PRNewswire/ ... "RegeneRx"), a clinical-stage drug development company focused on ... its licensee for RGN-137, GtreeBNT Co., Ltd., received ... its Phase 3 clinical trial design for RGN-137 ... dermal wound healing gel that incorporates Thymosin beta ...
(Date:2/27/2017)... February 27, 2017 Leading Countries, Technologies and ... is expected to grow at a CAGR of 8.9% from 2016-2021 ... grow at a CAGR of 9.1% from 2016 to 2027. The ... ... will benefit you Read on to discover how you can ...
Breaking Medicine Technology: